YIPF1

Across TCGA pan-cancer cohorts, YIPF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YIPF1 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher YIPF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated YIPF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

GBM, LUAD, and UCEC are the cancer types where YIPF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.256	0.487	.002	18	view →
LUAD	DFS	Median	All	0.473	0.767	.009	11	view →
UCEC	OS	Quartile	All	1.000	0.873	.018	4	view →
PDAC	DFS	Median	III,IV	0.532	0.249	.015	4	view →
HNSC	DFS	Median	III,IV	0.926	1.000	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YIPF1–GBM (DFS)

Open the GBM breakdown →